Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Cytotoxic chemotherapy
8 evidence topics · 8 sources
Chemotherapy responses without demonstrated survival benefit
Platinum plus fluorouracil versus methotrexate: randomized phase 3 trial
“Two hundred seventy-seven patients diagnosed with SCC of the head and neck were randomized to one of three treatments” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The complete and partial response rates were 32% for cisplatin plus 5-FU, 21% for carboplatin plus 5-FU, and 10% for MTX.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median response durations and median survival times were similar for all three treatment groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We conclude that combination chemotherapy resulted in improved response rates but was associated with an increased toxicity and no improvement in overall survival.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cisplatin plus paclitaxel versus cisplatin plus fluorouracil: randomized phase 3 trial
“Two hundred eighteen patients with locally advanced, recurrent, or metastatic disease were randomly assigned to CF (cisplatin 100 mg/m2 day 1 and fluorouracil 1,000 mg/m2/24 hours by continuous intravenous infusion day 1 through 4) or CP (cisplatin 75 mg/m2 day 1 and paclitaxel 175 mg/m2 over 3 hours on day 1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Estimated median survival was 8.7 months in the CF group and 8.1 month in the CP group. Objective response rate (complete response plus partial response) was 27% in the CF group and 26% in the CP group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 12 deaths occurred (CF, seven; CP, five) during treatment” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Taxane in place of fluorouracil with pembrolizumab: single-arm phase 4 trial
“Patients received pembrolizumab 200 mg intravenously once every 3 weeks for ≤35 cycles and carboplatin AUC 5 mg/mL/min intravenously once every 3 weeks for ≤6 cycles and investigator's choice of paclitaxel 100 mg/m2 on days 1 and 8 or 175 mg/m2 on day 1, intravenously once every 3 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At this final analysis, 49 (49%) of 101 patients had an objective response (95% CI, 38.4 to 58.7), including seven patients (7%) with a confirmed complete response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 101 treated patients, grade 3-5 and serious treatment-related adverse events occurred in 76 (75%) and 27 (27%), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pembrolizumab plus platinum plus taxane: United States real-world outcomes
“the toxicity of 5-FU has motivated the study of alternate combinations that replace 5-FU with a taxane.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study population comprised 83 individuals (80.7% male) with a median age of 64 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median (95% CI) rwOS was 14.9 (8.8-23.3) months, rwToT was 5.3 (4.0-8.2) months” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single-agent methotrexate, docetaxel, or cetuximab as the comparator after platinum
Single-agent standard therapy after platinum: response and survival in a phase 3 control arm
“The response rate was 13.3% in the nivolumab group versus 5.8% in the standard-therapy group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-related adverse events of grade 3 or 4 occurred in 13.1% of the patients in the nivolumab group versus 35.1% of those in the standard-therapy group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote